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patients’ scores decreased 67.7% on HAMD-17 and 69.5% on
HAMD-7 (P < 0.05). Improvements in SNRI-treated patients
were similar (64.6% and 63.2%, respectively, P < 0.05). There
were no signiﬁcant differences between groups in response rates
(P = 0.45 for HAMD-17, 0.16 for HAMD-7). Per-protocol (PP)
remission rates measured using HAMD-17 at week 8 were
58.3% for SSRI-treated patients (N = 72) and 48.4% for SNRI-
treated patients (N = 64, P = 0.30). For the HAMD-7 group, PP
remissions were 40.4% for SSRIs (N = 57) and 44.4% for SNRIs
(N = 81, P = 0.73). Intent-to-treat (ITT) remission rates using
HAMD-17 were 46.7% for SSRI-treated patients (N = 90) and
39.2% for SNRI-treated patients (N = 79, P = 0.41). HAMD-7
ITT remission rates were 33.3% for SSRIs (N = 69) and 36.4%
for SNRIs (N = 99; P = 0.81). By 8 weeks, 18.9% dropped out
in the SSRI group and 18.5% in the SNRI group (P = 0.95).
CONCLUSIONS: Large, randomized, controlled, primary care
data are needed to adequately address the question of superior-
ity between SNRIs and SSRIs. Our post –hoc analysis found no
signiﬁcant differences between these two therapeutic groups. Suf-
ﬁciently powered studies comparing the effectiveness of antide-
pressant therapies in real-world settings are urgently needed.
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OBJECTIVES: Compare adults treated with SSRIs and SNRIs
for major depression. METHODS: Identiﬁed all head-to-head
trials comparing SSRIs (citalopram, escitalopram, ﬂuoxetine, ﬂu-
voxamine, paroxetine, sertraline) with SNRIs (venlafaxine-XR,
duloxetine) in therapeutic doses. Outcome: remission 12) at 8
weeks. Two reviewers searched £ 7 or MADRS £ 3 or HAMD-
17 £(HAMD-7 Medline, Embase and Cochrane databases to
identify articles, extract data, adjudicated by a third judge. Rates
were combined using random-effects meta-analytic model. Per-
formed Intent-to-Treat (ITT) and Per-Protocol (PP) 2 assessed
heterogeneity of effects. RESULTS: 25 studies were c analyses.
identiﬁed, 19 were rejected; 6 studies provided 7 head-to-head
trials of 1345 patients (68.0% females per drug). Five RCTs (N
= 1008) and 2 naturalistic trials (N = 337). All displayed non-
heterogeneity (P > 0.05). ITT Remission rates in RCTs: 49.5%
(SE = 6.2%, n = 398) for SNRIs; 39.3% (SE = 10.0%, n = 369)
for SSRIs; meta-analytic difference 9.2% (CI95%:
3.0%–15.4%). PP rates—67.8% (SE = 7.5%, n = 297) for
SNRIs; 56.5% (SE = 10.9%, n = 269) for SSRIs; meta-analytic
difference 9.8% (CI95%:0.2%–19.5%). Naturalistic studies
produced ITT rates of 37.6% (SE = 3.6%, n = 178) for SNRIs;
40.2% (SE = 6.7%, n = 159) for SSRIs; a non-signiﬁcant (P =
0.69) difference of 2.1% favoring SSRIs. PP rates 46.2% (SE =
4.1%, n = 145) for SNRIs; 49.6% (SE = 9.0%, n = 129) for
SSRIs; a difference of 2.9% (P = 0.68) favoring SSRIs. ITT remis-
sion rates were 46.2% (SE = 5.1%, n = 737) for SNRIs; 39.5%
(SE = 7.2%, n = 608) for SSRIs; meta-analytic difference of 6.5%
(CI95%: 0.2%–12.8%). PP rates were 61.8% (SE = 6.9%, n =
571) and 54.5% (SE = 8.1%, n = 450); meta-difference was
6.4% (P = 0.13). CONCLUSIONS: SNRIs seem more efﬁca-
cious. Naturalistic studies produced non-signiﬁcant results dif-
fering from RCT results.
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OBJECTIVES: To compare indirectly the efﬁcacy and safety of
duloxetine and venlafaxine-XR, the two currently available sero-
tonin-norepinephrine reuptake inhibitors (SNRIs) in treating
major depressive disorder. METHODS: Outcomes from pub-
lished, randomized, placebo-controlled trials reporting on mod-
erately-to-severely depressed patients [Hamilton Rating Scale for
Depression (HAM-D) ≥ 15]. A systematic literature search was
performed (1996–January 2005) on Cochrane, EMBASE and
MEDLINE databases. Two independent reviewers judged the
trials for acceptance. Last Observation Carried Forward (LOCF)
data were extracted. Differences in remission (8-week HAM-D
score £7), response (50% decrease on HAM-D), and dropout
rates from lack of efﬁcacy (LOE) and adverse events (AEs) were
meta-analyzed using a random effects model. Each rate was con-
trasted from placebo. RESULTS: Data were acquired from 8
trials from 1754 patients for efﬁcacy and 1791 patients for dis-
continuation/safety. Venlafaxine-XR rates were 17.8% (CI95%:
9.0%–26.5%) and 24.4% (CI95%: 15.0%–37.7%) greater than
placebo for remission and response, compared to 14.2%
(CI95%: 8.9%–26.5%) and 18.6% (CI95%: 13.0%–24.2%) for
duloxetine. Although numerically higher for venlafaxine-XR, no
statistically signiﬁcant differences were found between drugs,
however, both demonstrated overall remission and response rates
signiﬁcantly higher than placebo (p < 0.001). Dropout rates 
due to AEs were, contrasted with placebo, for venlafaxine-XR
6.1% (CI95%: 2.5%–9.7%) and for duloxetine 5.7% (CI95%:
1.5%–10.0%) greater than placebo. Dropout rates due to LOE
were for venlafaxine—XR 10.7% (CI95%: 6.4%–15.1%) and
for duloxetine 11.1% (CI95%: 6.3%–15.9%) less than placebo.
Again, when the two drugs were compared, no statistically sig-
niﬁcant difference was found for both dropout rates. Reported
adverse events were comparable between drugs. CONCLU-
SIONS: Venlafaxine-XR tends to have a favorable trend in remis-
sion and response rates compared to duloxetine, but for dropout
rates and AE these agents did not differ. A direct comparison is
warranted to conﬁrm this tendency.
PMH45
COST EFFECTIVENESS OF DULOXETINE COMPARED WITH
VENLAFAXINE-XR IN THE TREATMENT OF MAJOR
DEPRESSIVE DISORDER
Van Baardewijk M1, Vis PM1, Einarson T2
1Univeristy of Utrecht, Utrecht,The Netherlands; 2University of
Toronto,Toronto, ON, Canada
OBJECTIVES: To determine the cost effectiveness of a new 
reuptake inhibitor, when compared with -XR in treating major
depressive disorder. METHODS: A cost effectiveness analysis,
using a decision tree modeled outpatient treatment over six
months. Analytic perspectives were those of society (all direct
and indirect costs) and the Ministry of Health of as payer for all
direct costs. Rates of success and dropouts were obtained from
a meta-analysis of placebo-controlled trials. Costs were taken
from standard lists, adjusted to 2005 Canadian dollars; dis-
counting was not applied. One-way sensitivity analyses were 
performed on monthly acquisition costs and success rates;
Monte-Carlo analysis examined all parameters over 10,000 iter-
ations. RESULTS: From both perspectives, outcomes all numer-
ically-XR (Expected success = 53% and 57%, Symptom-free
